What is McKesson's gross profit margin?

What were the key takeaways from McKesson's earnings call?

What is McKesson's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for McKesson year over year?

What guidance did McKesson's management provide for the next earnings period?

Did McKesson beat or miss consensus estimates last quarter?

What were the key takeaways from McKesson’s earnings call?

What is the market's earnings forecast for McKesson next quarter?

- **Revenue Growth Acceleration**: Q3 revenue up 11% to $106.2B, driven by oncology (+37%) and biopharma services.
- **AI-Driven Efficiency**: AI tools reduced DSCSA inquiries by 75%, with 100% service accuracy in Canada.
- **Margin Expansion**: Operating profit up 13% to $1.7B; Prescription Tech margin improved 138bps YoY, oncology operating profit +57%.
- **Shareholder Returns**: $680M share buybacks; TTM free cash flow $9.6B.
- **GLP-1 Momentum**: Sequential revenue growth 7%, oral GLP-1 launches poised to expand market.
- **Regulatory Adaptation**: Smooth IRA Part D implementation; MFN impact limited to 35% of oncology Medicare.

**【CEO Summary Section】**
- McKesson delivered Q3 revenue growth of 11% to $106.2 billion, driven by oncology, biopharma services, and North American distribution. 
- CEO emphasized strategic investments in AI and automation, citing a 75% reduction in DSCSA inquiries through AI chat tools and 100% service accuracy in Canada's digital operations.
- Full-year EPS guidance raised to $38.80-$39.20 (17-19% YoY growth), reflecting confidence in oncology and biopharma platforms.
- Separation of Medical-Surgical business on track for H2 2027 IPO, with $1 billion+ revenue contribution from Norway divestiture.

**【CFO Financial Commentary】**
- Q3 GAAP net income: $420 million; Non-GAAP EPS: $9.34 (16% YoY growth).
- Operating profit: $1.7 billion (13% YoY growth), driven by oncology (37% rev growth) and Prescription Tech Solutions (9% rev growth).
- Free cash flow: $1.1 billion; TTM free cash flow: $9.6 billion.
- Share buybacks: $680 million; Dividends: $101 million.
- FY26 outlook: 12-16% revenue growth, 13-17% operating profit growth.

**【Q&A Highlights】**
- **Technology Impact**: AI tools reduced annual verification workload by 75%, with $0.05 EPS accretion from tech investments.
- **Margin Expansion**: Prescription Tech margin improved 138bps YoY, oncology operating profit +57%.
- **Regulatory Resilience**: IRA Part D implementation seamless with partners; MFN impact limited to niche cash-pay patients.
- **GLP-1 Growth**: Sequential revenue growth 7%, oral GLP-1 launches expected to expand market.
- **Medical-Surgical Separation**: Transition services agreements in place; FY26 guidance assumes lower-end 2-6% growth due to illness season variability.

McKesson Corporation (MCK) Q3 2026 Earnings Call Transcript

- **Record Growth**: Q2 revenue up 10% to $103B, EPS up 39% to $9.86, driven by oncology and RxTS segments.
- **Strategic Reorganization**: New reporting structure highlights high-growth oncology and multispecialty platforms, with 2026 EPS guidance raised to $38.35-$38.85.
- **Automation Efficiency**: 75% reduction in manual processes via automation, enabling 570 bps operating expense leverage.
- **Acquisition Synergy**: PRISM and Core Ventures contribute 30%-34% of oncology segment's 2026 profit growth, ahead of initial targets.
- **Free Cash Flow Strength**: $2.2B Q2 free cash flow supports $907M in shareholder returns, with 2026 guidance for $4.4B-$4.8B free cash flow.

**【CEO Summary Section】**
- McKesson reported record second-quarter revenues of $103 billion, a 10% year-over-year increase, driven by strong performance across all segments.
- Adjusted EPS rose 39% to $9.86, reflecting operational efficiency and strategic investments.
- The company introduced a new reporting structure, separating oncology and multispecialty businesses to enhance growth visibility.
- Guidance for fiscal 2026 EPS was raised to $38.35-$38.85, up from $38.05-$38.55, citing organic growth and acquisitions.
- Investments in automation (e.g., order storage retrieval systems) reduced manual processes by 75%, improving efficiency.
- The Medical-Surgical Solutions business is expected to be spun off by mid-2027, with 2026 guidance assuming full ownership.

**【CFO Financial Commentary】**
- Gross profit increased 9% to $3.5 billion, driven by oncology and pharmaceutical distribution growth.
- Operating expenses decreased 1% to $2 billion, with a 570 basis point improvement in operating expense ratio.
- Oncology and multispecialty segment operating profit rose 71% to $397 million, with 50% growth from PRISM and Core Ventures acquisitions.
- Prescription Technology Solutions (RxTS) operating profit grew 20% to $261 million, fueled by prior authorization services for GLP-1 medications.
- Free cash flow for the quarter was $2.2 billion, supporting $907 million in shareholder returns (share buybacks and dividends).
- Full-year revenue growth guidance is 11%-15%, with oncology and RxTS segments expected to lead at 27%-31% and 9%-13% growth rates, respectively.

**【Q&A Highlights】**
- **Margin Expansion**: RxTS segment's 20% operating profit growth reflects mix shift to higher-margin technology services (e.g., prior authorization). Oncology segment's 71% profit growth includes $51 million from market decisions and equity gains.
- **Regulatory Impact**: Drug Supply Chain Security Act implementation had minimal disruption, enhancing supply chain transparency and customer stickiness.
- **Acquisition Performance**: PRISM and Core Ventures contributed 30%-34% of oncology segment's 2026 operating profit growth, slightly ahead of initial $0.40-$0.60 EPS accretion targets.
- **Risk Factors**: Medical-Surgical Solutions segment faces quarterly volatility due to illness season products (e.g., vaccines), which caused a 4% revenue headwind in Q2.

McKesson Corporation (MCK) Q2 2026 Earnings Call Transcript

- **Record Q1 Growth**: $97.8B revenue (+23% YoY), $1.4B operating profit (+9% YoY), with oncology and RxTS leading the charge.
- **Strategic Expansion**: Acquisitions of Core Ventures and PRISM Vision expand oncology network to 3,300 providers, driving 6-7% operating profit growth.
- **Automation Efficiency**: 90% automated distribution centers and cobots reduce costs, improving OpEx to Gross Profit ratio by 450+ basis points.
- **Guidance Uptick**: Full-year EPS raised to $37.10-$37.90, reflecting strong Q1 and acquisition synergies.
- **Biosimilar Momentum**: Consistent contributor to oncology growth; Eylea biosimilar launch poised to enhance retina platform.


**【CEO Summary Section】**
- **Record Q1 Results**: Delivered $97.8 billion in revenue (23% YoY growth) and $1.4 billion in adjusted operating profit (9% YoY growth). Raised full-year EPS guidance to $37.10-$37.90.
- **Strategic Acquisitions**: Completed acquisitions of Core Ventures (Florida Cancer Specialists) and PRISM Vision, expanding oncology and ophthalmology platforms to ~3,300 providers across 700 sites.
- **Growth Pillars**: Oncology and biopharma services drove double-digit growth, with Prescription Technology Solutions (RxTS) revenue up 16% and operating profit up 21%.
- **Community Impact**: Supported employees through hardships with $700+ grants; highlighted Health Mart's top ranking in J.D. Power pharmacy study.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income $420M; Non-GAAP EPS $8.26 (5% YoY growth). Operating expenses decreased 1% due to cost optimization and automation.
- **Segment Performance**: U.S. Pharmaceutical segment revenue +25% (GLP-1 meds $12.1B, +38% YoY); RxTS operating profit +21% driven by prior auth services.
- **Automation Investments**: 90% automated distribution centers and cobots in specialty facilities improve efficiency and safety.
- **Full-Year Guidance**: Revenue +11-15%, operating profit +9-13%; U.S. Pharmaceutical segment growth expected at high end of 12-16% range.

**【Q&A Key Highlights】**
- **RxTS Growth**: Q1 operating profit up 21% due to GLP-1 prior auth; 2026 outlook for 9-13% growth driven by program maturation and new launches.
- **Specialty Pharma**: 10%+ YoY growth in cold chain lines; automation investments support long-term resiliency.
- **Norway Sale**: Expected $0.20 EPS impact from held-for-sale accounting; final European exit on track.
- **Biosimilars**: Steady contributor to oncology growth; Eylea biosimilar launch expected to benefit retina platform post-PRISM integration.
- **Market Risks**: Tariffs and coverage changes (e.g., Medicaid cuts) seen as long-term, non-material threats to demand.


McKesson Corporation (MCK) Q1 2026 Earnings Call Transcript

- **Revenue & EPS Beat**: FY25 revenue up 16% to $359B, EPS of $33.05 (+20% YoY), exceeding guidance.
- **Strategic Acquisitions**: $2.49B Core Ventures deal adds 530 oncology providers; PRISM Vision to boost ophthalmology care.
- **Free Cash Flow Strength**: $5.2B in FY25, with $4.4B-$4.8B guided for FY26, enabling $2.5B buybacks.
- **GLP-1 Momentum**: Q4 GLP-1 sales $10.9B (+46% YoY), driving 15% growth in prior auth volumes.
- **Medical Surgical Spin-Off**: Separation to unlock value, focusing capital on high-growth oncology and biopharma segments.


**【CEO Summary Section】**
- **Record Revenue Growth**: Full-year consolidated revenues reached $359 billion, up 16% YoY, driven by double-digit growth in U.S. pharmaceutical and prescription tech segments.
- **Strategic Acquisitions**: Completed acquisition of PRISM Vision (80% ownership) and pending acquisition of Core Ventures (70% ownership), adding 530 oncology providers and enhancing specialty care capabilities.
- **Operational Excellence**: Generated $5.2 billion in free cash flow, returning $3.5 billion to shareholders through buybacks and dividends.
- **2026 Outlook**: Guided for 11-15% revenue growth and $36.75-$37.55 EPS, with oncology and biopharma services as key growth drivers.

**【CFO Financial Commentary】**
- **Q4 Financials**: GAAP EPS of $10.12 (20% YoY growth), driven by 19% revenue increase to $90.8 billion and 24% operating profit growth to $1.6 billion.
- **Segment Performance**: U.S. pharmaceutical segment grew 21% to $83.2 billion, fueled by GLP-1 drug sales ($10.9 billion Q4, +46% YoY). Prescription tech segment operating profit rose 34% to $285 million.
- **Cost Optimization**: Achieved $100 million in cost savings in medical surgical segment, supporting 15% operating profit growth.
- **Free Cash Flow**: $7.5 billion in Q4, with $4.4-$4.8 billion guided for FY26, supporting $2.5 billion in share buybacks.

**【Q&A Key Takeaways】**
- **MFN Policy Risk**: CEO emphasized community-based oncology's cost-effectiveness and advocacy for fair reimbursement, while CFO noted no material impact on FY26 guidance.
- **Tariff Impact**: Diversified sourcing strategies mitigate risks, with no expected material impact on FY26 results.
- **Medical Surgical Separation**: Plans to spin off medical segment into independent company to focus capital on high-growth oncology and biopharma platforms.
- **GLP-1 Growth**: Access solutions drove 15% YoY increase in prior auth volumes, with PRISM and Core Ventures expected to add $0.20-$0.60 to FY26 EPS.


McKesson Corporation (MCK) Q4 2025 Earnings Call Transcript

- **Record Q3 Growth**: $95.3B revenue (+18% YoY), $1.5B adj. op. profit (+16%), driven by specialty drugs and Rx tech solutions.
- **Strategic Expansion**: $850M PRISM Vision acquisition to build leading retinal care platform, with $0.65-$0.75 EPS accretion by year 3.
- **Segment Strength**: U.S. pharmaceutical up 19%, GLP-1 revenue +45%; Rx tech solutions op. profit +22%; medical surgical cost savings on track for $100M FY25.
- **2026 Vision**: 12%-14% EPS growth fueled by oncology network (2,750+ providers), specialty drug pipeline, and integrated retinal care platform.
- **Risks**: Public policy changes, formulary shifts (e.g., $320M impact), and quarterly GLP-1 volatility, but diversified portfolio provides resilience.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 revenue reached $95.3 billion, up 18% YoY, driven by U.S. pharmaceutical and prescription tech solutions. Adjusted operating profit rose 16% to $1.5 billion.
- **Strategic Acquisitions**: Signed agreement to acquire 80% stake in PRISM Vision for $850M, expected to be $0.20-$0.30 EPS accretive in first 12 months and $0.65-$0.75 by year 3. This expands specialty services in retina and ophthalmology.
- **Segment Performance**: U.S. pharmaceutical segment grew 19%, led by specialty drugs (e.g., GLP-1 meds up 45%). Prescription tech solutions saw 14% revenue growth. Medical surgical faced softer-than-expected illness season, but cost optimization initiatives on track to deliver $100M savings.
- **Guidance Update**: Narrowed FY25 EPS guidance to $32.55-$32.95 (19%-20% growth), reflecting confidence in oncology, biopharma services, and core distribution.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income $420M, Non-GAAP EPS $8.03 (up 4% YoY). Operating expenses rose 2% to $1.9B, but operating profit margin improved 250bps due to cost controls and automation.
- **Segment Insights**: U.S. pharmaceutical segment saw $3.4B GLP-1 revenue growth. Prescription tech solutions operating profit up 22%. Medical surgical operating profit +4% despite revenue decline, driven by cost savings.
- **Cash Flow**: Generated $1.1B cash, returned $919M to shareholders (shares repurchased at $537 avg price). FY25 free cash flow expected $4.8B-$5.2B.

**【Q&A Key Themes】**
- **2026 Outlook**: Affirmed 12%-14% long-term EPS growth, citing oncology network expansion (2,750+ providers), specialty drug pipeline, and Rx tech solutions. PRISM acquisition aligns with proven oncology platform strategy.
- **MedSurg Challenges**: Soft illness season (IQVIA severity at 62% of 5-year avg) and primary care weakness. Cost optimization initiatives to better align with alternate-site demand.
- **PRISM Synergies**: Leveraging existing GPO, practice management, and clinical research capabilities to create integrated retinal care platform. Similar to oncology strategy, focusing on distribution, services, and data/analytics.
- **Risks**: Public policy uncertainty, formulary changes (e.g., $320M impact from one PBM formulary shift), and quarterly GLP-1 volatility. However, diversified portfolio mitigates risk.


MCK

MCK fundamentals

Earnings Call

You can ask Aime